Breakthrough data validates capabilities of GlueSEEKER platform to identify novel induced protein-protein interactions and expand druggable space ...

SCOPE trial of SCIB1/iSCIB1+ plus standard of care shows excellent results encompassing efficacy, durability, immune responses and safety ...

WATERTOWN, MA, USA and GOSSELIES, Belgium I July 21, 2025 I iTeos Therapeutics, Inc. (“iTeos”) (Nasdaq: ITOS) today announced that it has entered into a ...

Patients switched to donidalorsen without increased breakthrough attacks and experienced further reductions in mean attack rate from baseline – ...

CAMBRIDGE, MA, USA I July 21, 2025 I Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on ...

HOLON, Israel I July 21, 2025 I Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in predictive ...

SAN FRANCISCO, CA, USA I July 21, 2025 I AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd. (collectively AusperBio), a clinical-stage biotechnology ...

I Orion’s collaboration partner Bayer announced today that the European Commission has granted marketing authorization in the European Union ...

PARIS, France I July 22, 2025 I Sanofi today announces it has entered into an agreement to acquire Vicebio Ltd (“Vicebio”), a privately held biotechnology company headquartered in London, UK. The ...

PARIS, France I July 21, 2025 I Corteria Pharmaceuticals, a clinical-stage biopharmaceutical company focused on the development of transformative ...

STUTTGART, Germany I July 21, 2025 I La Merie Publishing released its newest product entitled: TL1A Inhibitors & DR3 Antagonists: a Competitor Analysis ...

The pivotal Phase IIb ALIENTO study met the primary endpoint of a statistically significant reduction in the annualized exacerbation rate (AER) at 52 weeks ...